1. Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors

   • Ernest Nadal
   • Bartomeu Massuti
   • Enriqueta Felip

   Review 06 February 2019 Pages: 341 - 352

2. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma

   • Boyang Chang
   • Tao Huang
   • Peihong Wu

   Original Article Open access 01 December 2018 Pages: 353 - 363

   

3. CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions

   • Wanghong Hu
   • Zhenguo Zi
   • Fang Wei

   Original Article 06 December 2018 Pages: 365 - 377

   

4. Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model

   • Diana Llopiz
   • Marta Ruiz
   • Pablo Sarobe

   Original Article 13 December 2018 Pages: 379 - 393

   

5. Ex vivo conditioning with IL-12 protects tumor-infiltrating CD8⁺ T cells from negative regulation by local IFN-γ

   • Lin Lin
   • Patricia Rayman
   • C. Marcela Diaz-Montero

   Original Article 14 December 2018 Pages: 395 - 405

   

6. Identification and characterization of an alternative cancer-derived PD-L1 splice variant

   • Nadia B. Hassounah
   • Venkat S. Malladi
   • Esra A. Akbay

   Original Article 18 December 2018 Pages: 407 - 420

   

7. A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression

   • Kathleen M. Mahoney
   • Sachet A. Shukla
   • Gordon J. Freeman

   Original Article Open access 18 December 2018 Pages: 421 - 432

   

8. Immune cell infiltration as a biomarker for the diagnosis and prognosis of stage I–III colon cancer

   • Rui Zhou
   • Jingwen Zhang
   • Wangjun Liao

   Original Article Open access 19 December 2018 Pages: 433 - 442

   

9. Distinct immunological properties of the two histological subtypes of adenocarcinoma of the ampulla of Vater

   • Min Hwan Kim
   • Mi Jang
   • Hye Jin Choi

   Original Article 02 January 2019 Pages: 443 - 454

   

10. The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice

    • Hussein Sultan
    • Takumi Kumai
    • Esteban Celis

    Original Article 02 January 2019 Pages: 455 - 466

    

11. CD73 expression in normal and pathological human hepatobiliopancreatic tissues

    • Amedeo Sciarra
    • Inês Monteiro
    • Laurence de Leval

    Original Article 04 January 2019 Pages: 467 - 478

    

12. Chronic retroviral infection of mice promotes tumor development, but CD137 agonist therapy restores effective tumor immune surveillance

    • Anna Malyshkina
    • Elisabeth Littwitz-Salomon
    • Ulf Dittmer

    Original Article 11 January 2019 Pages: 479 - 488

    

13. STAT3 inhibition specifically in human monocytes and macrophages by CD163-targeted corosolic acid-containing liposomes

    • Morten Nørgaard Andersen
    • Anders Etzerodt
    • Holger J. Møller

    Original Article 14 January 2019 Pages: 489 - 502

    

14. The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial

    • Charlotte M. Huijts
    • Sinéad M. Lougheed
    • for the Dutch WIN-O Consortium

    Original Article Open access 17 January 2019 Pages: 503 - 515

    

15. Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer

    • Alberto A. Chiappori
    • Charles C. Williams
    • Scott J. Antonia

    Clinical Trial Report Open access 27 December 2018 Pages: 517 - 527

    

16. Correction to: CD73 expression in normal and pathological human hepatobiliopancreatic tissues

    • Amedeo Sciarra
    • Inês Monteiro
    • Laurence de Leval

    Correction 05 February 2019 Pages: 529 - 529